• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Hercules Capital Inc.

    6/11/25 5:22:13 PM ET
    $HTGC
    Investment Managers
    Finance
    Get the next $HTGC alert in real time by email
    FWP 1 d77552dfwp.htm FWP FWP

    Filed pursuant to Rule 433

    Issuer Free Writing Prospectus dated June 11, 2025

    Relating to Preliminary Prospectus Supplement dated June 11, 2025 and

    Prospectus dated December 11, 2024

    Registration No. 333-283735

    Hercules Capital, Inc.

    $350,000,000

    6.000% Notes due 2030

    PRICING TERM SHEET

    June 11, 2025

    The following sets forth the final terms of the 6.000% Notes due 2030 and should only be read together with the preliminary prospectus supplement dated June 11, 2025, together with the accompanying prospectus dated December 11, 2024, relating to these securities (the “Preliminary Prospectus”), and supersedes the information in the Preliminary Prospectus to the extent inconsistent with the information in the Preliminary Prospectus. In all other respects, this pricing term sheet is qualified in its entirety by reference to the Preliminary Prospectus. Terms used herein but not defined herein shall have the respective meanings as set forth in the Preliminary Prospectus. All references to dollar amounts are references to U.S. dollars.

     

    Issuer    Hercules Capital, Inc.
    Issuer Ticker    HTGC
    Security    6.000% Notes due 2030 (the “Notes”)
    Ratings*    Baa3 (Positive) (Moody’s); BBB- (Stable) (Fitch)
    Trade Date    June 11, 2025
    Settlement Date    June 16, 2025 (T+3)
    Aggregate Principal Amount Offered    $350,000,000
    Maturity    June 16, 2030, unless earlier repurchased or redeemed
    Price to Public (Issue Price)    98.907%
    Coupon (Interest Rate)    6.000%
    Yield to Maturity    6.258%
    Spread to Benchmark Treasury    +225 basis points
    Benchmark Treasury    4.000% due May 31, 2030
    Benchmark Treasury Price and Yield    99-30 3⁄4 / 4.008%


    Interest Payment Dates    June 16 and December 16, commencing December 16, 2025
    Optional Redemption    Prior to May 16, 2030 (one month prior to their maturity date) (the “Par Call Date”), we may redeem the Notes at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:
      

    (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the Notes matured on the Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 35 basis points less (b) interest accrued to, but not including, the date of redemption, and

      

    (2) 100% of the principal amount of the Notes to be redeemed,

       plus, in either case, accrued and unpaid interest thereon to, but not including, the redemption date.
       On or after the Par Call Date, we may redeem the Notes, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the Notes being redeemed plus accrued and unpaid interest thereon to, but not including, the redemption date.
    Change of Control    Holders have the right to require Hercules Capital, Inc. to repurchase the Notes at 100% of their principal amount plus accrued and unpaid interest, if any, in the event of a change of control repurchase event.
    Denomination    $2,000 and integral multiples of $1,000 in excess thereof
    CUSIP    427096 AN2
    ISIN    US427096AN29
    Joint Book-Running Managers    Goldman Sachs & Co. LLC
    SMBC Nikko Securities America, Inc.
    Co-Managers:   

    MUFG Securities Americas Inc.

     

    Zions Direct, Inc.

     

    RBC Capital Markets, LLC

     

    Synovus Securities, Inc.

     

    Keefe, Bruyette & Woods, Inc.

     

    *

    Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. Each securities rating should be evaluated independent of each other securities rating.

    Hercules Capital, Inc. expects that delivery of the Notes will be made to investors on or about June 16, 2025, which will be the third business day following the date hereof. Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade Notes prior to the business day before the delivery of the Notes hereunder will be required, by virtue of the fact that the Notes initially settle in T+3, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the Notes who wish to trade the Notes prior to their date of delivery should consult their advisors.

     

    2


    Investors are advised to carefully consider the investment objectives, risks, charges and expenses of Hercules Capital, Inc. before investing. The Preliminary Prospectus, which has been filed with the Securities and Exchange Commission (the “SEC”), contains this and other information about Hercules Capital, Inc. and should be read carefully before investing.

    The information in the Preliminary Prospectus and in this pricing term sheet is not complete and may be changed. The Preliminary Prospectus and this pricing term sheet are not offers to sell any securities of Hercules Capital, Inc. and are not soliciting an offer to buy such securities in any jurisdiction where such offer and sale is not permitted.

    An effective shelf registration statement relating to these securities is on file with the SEC. The offering may be made only by means of a preliminary prospectus supplement and an accompanying prospectus. Copies of the Preliminary Prospectus may be obtained from Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, or email [email protected], or telephone: 1-866-471-2526, or SMBC Nikko Securities America, Inc., 277 Park Avenue, New York, New York 10172, or email [email protected], or telephone: 1-212-224-5135.

     

    3

    Get the next $HTGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HTGC

    DatePrice TargetRatingAnalyst
    12/12/2024$19.50 → $21.50Mkt Perform → Outperform
    Keefe Bruyette
    1/16/2024$17.00 → $17.50Buy → Neutral
    Compass Point
    11/21/2023$17.00Neutral
    UBS
    8/30/2023$17.50Neutral → Buy
    Compass Point
    8/4/2023$13.50 → $17.00Underperform → Mkt Perform
    Keefe Bruyette
    4/6/2023$16.00Neutral → Overweight
    Piper Sandler
    3/13/2023$14.50 → $10.50Mkt Perform → Underperform
    Keefe Bruyette
    7/29/2022Outperform → Perform
    Oppenheimer
    More analyst ratings

    $HTGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hercules Capital Renews and Increases Its Credit Facility with MUFG Bank, Ltd. to $440.0 Million

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has upsized and renewed its existing $400.0 million credit facility with MUFG Bank, Ltd. ("MUFG") with an upsized credit facility under which Goldman Sachs Bank USA, Autobahn Funding Company LLC, City National Bank, a National Banking Association, Umpqua Bank, Valley National Bank, Citizens Bank, N.A., Zions Bancorporation, N.A., dba California Bank & Trust and Mitsubishi HC Capital America, Inc. toge

      6/12/25 4:04:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Prices Upsized Institutional Notes Offering of $350.0 Million 6.000% Notes due 2030

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has priced an upsized underwritten public offering of $350.0 million in aggregate principal amount of 6.000% notes due June 2030 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on June 16, 2025. The Notes are unsecured and bear interest at a rate of 6.000% per year, payable semiannually and will mature on June 16, 2030 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company expects to use the net pro

      6/11/25 5:19:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

      GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company's pemvidutide development plans and financing needs. Access to this additional capital strengthens Altimmune's ba

      5/13/25 7:00:00 AM ET
      $ALT
      $HTGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance

    $HTGC
    SEC Filings

    See more
    • SEC Form FWP filed by Hercules Capital Inc.

      FWP - Hercules Capital, Inc. (0001280784) (Subject)

      6/11/25 5:22:13 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form 497AD filed by Hercules Capital Inc.

      497AD - Hercules Capital, Inc. (0001280784) (Filer)

      6/11/25 5:16:36 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form 497AD filed by Hercules Capital Inc.

      497AD - Hercules Capital, Inc. (0001280784) (Filer)

      6/10/25 4:54:50 PM ET
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $HTGC
    Leadership Updates

    Live Leadership Updates

    See more

    $HTGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hercules Capital upgraded by Keefe Bruyette with a new price target

      Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously

      12/12/24 8:09:58 AM ET
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital downgraded by Compass Point with a new price target

      Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously

      1/16/24 8:29:29 AM ET
      $HTGC
      Investment Managers
      Finance
    • UBS initiated coverage on Hercules Capital with a new price target

      UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00

      11/21/23 7:31:43 AM ET
      $HTGC
      Investment Managers
      Finance
    • Revelation Partners Expands Team with Hire of Andrew Olson, Partner, Chief Financial Officer & Chief Operating Officer

      SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

      11/29/23 1:01:00 PM ET
      $HTGC
      $TPVG
      Investment Managers
      Finance
      Other Consumer Services
      Consumer Discretionary
    • Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc

      9/25/23 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Announces the Appointment of Ms. DeAnne Aguirre to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o

      6/24/22 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Chief Operating Officer Follmann Christian sold $7,043 worth of shares (395 units at $17.83) and bought $7,043 worth of shares (395 units at $17.83), increasing direct ownership by 0.22% to 121,212 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      6/5/25 6:38:34 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:23 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:04 PM ET
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Follmann Christian sold $7,043 worth of shares (395 units at $17.83) and bought $7,043 worth of shares (395 units at $17.83), increasing direct ownership by 0.22% to 121,212 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      6/5/25 6:38:34 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:23 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:04 PM ET
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Financials

    Live finance-specific insights

    See more
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2025 Annual Meeting of Stockholders by virtual meeting on Wednesday, June 18, 2025 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 24, 2025 and mailed to stockholders of record as of April 17, 2025. 2025 Annual Meeting of Stockholders June 18, 2025 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2025 Matters to be voted on include: 1) election of three directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common stock

      5/8/25 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Reports First Quarter 2025 Financial Results

      Q1 2025 Total Gross Debt and Equity Commitments of $1.02 Billion Q1 2025 Total Gross Fundings of $539.1 Million Q1 2025 Total Investment Income of $119.5 Million Q1 2025 Net Investment Income "NII" of $77.5 Million, or $0.45 per Share Q1 2025 NII of $0.45 per Share, provides 113% Coverage of the Base Cash Distribution Received an Investment Grade Rating Upgrade to BBB (high) from Morningstar DBRS Closed Offering of $287.5 Million of 4.750% Convertible Unsecured Notes due 2028 Conservative Balance Sheet Management with Net GAAP Leverage of 97.4% and Net Regulatory Leverage of 82.7%(1) Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-Owned Subsidiary, Hercule

      5/1/25 4:04:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hercules Capital Inc.

      SC 13G - Hercules Capital, Inc. (0001280784) (Subject)

      5/8/23 5:06:26 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form SC 13G/A filed by Hercules Capital Inc. (Amendment)

      SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)

      10/12/22 9:11:00 AM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form SC 13G filed by Hercules Capital Inc.

      SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)

      4/27/22 4:31:08 PM ET
      $HTGC
      Investment Managers
      Finance